Essex Investment Management Co. LLC Has $2.02 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)

Essex Investment Management Co. LLC decreased its position in Evolus, Inc. (NASDAQ:EOLS) by 38.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 182,503 shares of the company’s stock after selling 113,050 shares during the period. Essex Investment Management Co. LLC owned 0.29% of Evolus worth $2,015,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Creative Planning boosted its stake in shares of Evolus by 23.7% in the 3rd quarter. Creative Planning now owns 15,451 shares of the company’s stock valued at $250,000 after purchasing an additional 2,963 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in Evolus by 335.3% in the third quarter. GSA Capital Partners LLP now owns 120,964 shares of the company’s stock valued at $1,960,000 after buying an additional 93,176 shares during the period. Oppenheimer & Co. Inc. bought a new position in Evolus in the third quarter valued at approximately $212,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Evolus during the 3rd quarter worth $940,000. Finally, Intech Investment Management LLC acquired a new stake in Evolus during the 3rd quarter worth $228,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on EOLS shares. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research report on Wednesday, March 5th. Barclays raised their target price on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Wednesday, March 5th.

Evolus Price Performance

Shares of EOLS stock opened at $13.58 on Monday. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 12-month low of $9.25 and a 12-month high of $17.82. The firm has a fifty day moving average of $12.95 and a 200-day moving average of $14.05. The firm has a market capitalization of $863.51 million, a price-to-earnings ratio of -14.92 and a beta of 1.28.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.